There is a lack of high quality, standardized data on AB use and AMR in neonates and children worldwide.
This limits ability to develop sustainable and widely applicable strategies for minimizing selection of AMR, defining effective antibiotic treatment approaches and instituting infection control measures.
What is GARPEC?
Global Antimicrobial Resistance, Prescribing, and Efficacy Among Neonates and Children
The GARPEC project is a Penta-sponsored global surveillance network focused on collection of data on neonatal and pediatric antimicrobial prescribing and resistance. Its main functions are to collect and analyze data on antimicrobial prescriptions among neonates and children and on the organisms causing blood stream infections in these populations, including their antibiotic/antifungal resistance patterns.
Why is GARPEC needed?
The network addresses the current lack of quality, standardized data on antimicrobial use and resistance among neonatal and pediatric patients, data which are essential for characterizing the problem of antimicrobial resistance worldwide and developing effective treatment and control strategies at the local level.
What is GARPEC’s goal?
GARPEC aims to characterize antimicrobial prescription rates among neonatal and pediatric patients
using periodic point prevalence surveys and to assess bloodstream infection (BSI) burden and resistance
patterns among neonatal and pediatric patients using routinely collected laboratory data.
This project is funded by Penta.